Table 1.

Dose time interacting effect of mycotoxins on relative cell viability (%). CFSCP: Cell-free supernatant of compound probiotics; MDE: Mycotoxin degradation enzyme.

Groups	6 h	12 h	18 h	24 h	48 h
Z500	83.48 ± 4.26Cb	101.79 ± 6.60Aa	94.18 ± 6.39Bab	90.15 ± 6.21Bc	103.72 ± 3.35Aa
A40	82.83 ± 3.48Cbc	95.04 ± 3.04Bb	94.94 ± 3.98Bab	97.72 ± 2.35Ba	103.48 ± 3.33Aa
Z500 + A40	81.02 ± 4.02Ccd	85.70 ± 5.77BCc	87.24 ± 6.62BCcd	88.63 ± 4.27ABbc	94.56 ± 4.21Abc
Z1000	79.40 ± 3.67Bcd	92.02 ± 5.61Ab	93.50 ± 3.69Aab	91.45 ± 6.47Ab	94.91 ± 5.90Abc
A80	81.58 ± 3.37Cbc	92.30 ± 3.21ABb	91.73 ± 3.63Bbc	95.84 ± 4.66ABa	97.27 ± 5.90Ab
Z1000 + A80	75.45 ± 5.81Cd	85.35 ± 7.28ABc	83.99 ± 4.44Bd	81.64 ± 2.72Bd	90.96 ± 3.78Ac
CFSCP + MDE	98.56 ± 0.45Aa	99.12 ± 0.67Aa	98.36 ± 0.06Aa	98.96 ± 0.43Aa	98.15 ± 0.55Ab

Note: Data with different lowercase letters in the same column significantly differ from each other (p < 0.05), while data with the same lowercase letter in the same column insignificantly differ from each other (p > 0.05). Data with different capital letters in the same row significantly differ from each other (p < 0.05), while data with the same capital letter in the same row insignificantly differ from each other (p > 0.05). The relative viability of IPEC-J2 cells (%) = (A490 in treated group - A630 in treated group)/(A490 in control group - A630 in control group) × 100. Z500 and Z1000 mean 500 and 1000 µg/L zearalenone (ZEA); A40 and A80 mean 40 and 80 µg/L aflatoxin B₁ (AFB₁).